Annexon appoints Mark Blumenkranz to board; Muneer Satter steps down after 11 years

Annexon, Inc.

Mark S. Blumenkranz appointed to Annexon board effective Aug 10, 2026, as Class II director with term to 2028 annual meeting.
He joins Audit Committee and Science and Technology Committee; receives $40k annual retainer and 175k-share initial option grant.
Muneer Satter resigned as director and committee roles effective immediately prior to Blumenkranz appointment; no disagreement cited.
Blumenkranz is Stanford emeritus professor; co-founded Adverum, Optimedica, Oculeve, Kedalion; retinal expertise relevant to vonaprument.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.